InvestorsHub Logo
Followers 65
Posts 23762
Boards Moderated 0
Alias Born 11/23/2016

Re: None

Saturday, 03/30/2019 10:11:02 AM

Saturday, March 30, 2019 10:11:02 AM

Post# of 613
No one, but Ron Perelman, seems exited about the posthoc subgroup study of 15 diabetes type 2 patients and the prospect of approval for Azeliragon.

What happened, are retail investors no longer duped by Perelman’s purchases?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VTVT News